| mRNA |
myricetin |
CTRPv2 |
pan-cancer |
AAC |
0.0066 |
0.9 |
| mRNA |
CIL55A |
CTRPv2 |
pan-cancer |
AAC |
0.0086 |
0.9 |
| mRNA |
masitinib |
CTRPv2 |
pan-cancer |
AAC |
0.0061 |
0.9 |
| mRNA |
Rapamycin |
GDSC1000 |
pan-cancer |
AAC |
0.0081 |
0.9 |
| mRNA |
cabozantinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0061 |
0.9 |
| mRNA |
dinaciclib |
CTRPv2 |
pan-cancer |
AAC |
-0.0079 |
0.9 |
| mRNA |
17-AAG |
FIMM |
pan-cancer |
AAC |
0.027 |
0.9 |
| mRNA |
17-AAG |
GDSC1000 |
pan-cancer |
AAC |
-0.0051 |
0.9 |
| mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0056 |
0.9 |
| mRNA |
vorinostat:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0053 |
0.9 |